Here's why Big Pharma wants to be in rare diseases--and why Sanofi ($SNY) made its $20.1 billion play for Genzyme. The company has slapped a price tag on its new oral treatment for Gaucher disease, Cerdelga: $310,250 per year. Report
Here's why Big Pharma wants to be in rare diseases--and why Sanofi ($SNY) made its $20.1 billion play for Genzyme. The company has slapped a price tag on its new oral treatment for Gaucher disease, Cerdelga: $310,250 per year. Report